Abivax S.A.
AAVXF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $2,017 | $4,006 | $6,786 | $2,245 |
| % Growth | -49.7% | -41% | 202.3% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $378 |
| Gross Profit | $2,017 | $4,006 | $6,786 | $1,867 |
| % Margin | 100% | 100% | 100% | 83.2% |
| R&D Expenses | $77,946 | $81,882 | $64,650 | $70,554 |
| G&A Expenses | $16,303 | $15,014 | $17,932 | $15,632 |
| SG&A Expenses | $17,837 | $16,739 | $22,161 | $21,908 |
| Sales & Mktg Exp. | $1,534 | $1,725 | $4,229 | $6,276 |
| Other Operating Expenses | -$70 | -$1,628 | -$28 | $0 |
| Operating Expenses | $95,713 | $96,993 | $86,783 | $95,592 |
| Operating Income | -$93,696 | -$92,987 | -$79,997 | -$90,177 |
| % Margin | -4,645.3% | -2,321.2% | -1,178.9% | -4,016.8% |
| Other Income/Exp. Net | -$7,088 | -$1,617 | -$4,306 | -$7,949 |
| Pre-Tax Income | -$100,784 | -$94,604 | -$81,638 | -$95,787 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$100,784 | -$94,604 | -$81,638 | -$95,787 |
| % Margin | -4,996.7% | -2,361.6% | -1,203% | -4,266.7% |
| EPS | -1.59 | -1.5 | -1.3 | -1.91 |
| % Growth | -6% | -15.4% | 31.9% | – |
| EPS Diluted | -1.59 | -1.5 | -1.3 | -1.91 |
| Weighted Avg Shares Out | 63,410 | 63,174 | 62,919 | 50,228 |
| Weighted Avg Shares Out Dil | 63,410 | 63,174 | 62,919 | 50,228 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $4,811 | $0 |
| Interest Expense | $7,007 | $1,105 | $7,891 | $5,700 |
| Depreciation & Amortization | $102 | $929 | $171 | $130 |
| EBITDA | -$93,594 | -$92,058 | -$79,825 | -$90,047 |
| % Margin | -4,640.3% | -2,298% | -1,176.3% | -4,011% |